Midatech Pharma (NASDAQ: MTP) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Midatech Pharma to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.
Institutional & Insider Ownership
0.4% of Midatech Pharma shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.4% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Midatech Pharma and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Midatech Pharma||$9.79 million||-$20.70 million||-0.52|
|Midatech Pharma Competitors||$2.03 billion||$140.19 million||-2.04|
Midatech Pharma’s rivals have higher revenue and earnings than Midatech Pharma. Midatech Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Midatech Pharma and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Midatech Pharma Competitors||3756||10982||25004||829||2.56|
As a group, “Pharmaceutical preparations” companies have a potential upside of 60.04%. Given Midatech Pharma’s rivals higher probable upside, analysts clearly believe Midatech Pharma has less favorable growth aspects than its rivals.
This table compares Midatech Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Midatech Pharma Competitors||-2,632.88%||-80.14%||-24.47%|
Risk and Volatility
Midatech Pharma has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Midatech Pharma’s rivals have a beta of 1.17, indicating that their average stock price is 17% more volatile than the S&P 500.
Midatech Pharma Company Profile
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.